PL3294740T3 - Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych - Google Patents

Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych

Info

Publication number: PL3294740T3
Authority: PL; Poland
Prior art keywords: prophylaxis; derivatives; novel; treatment; virus infection
Prior art date: 2015-05-08

Application number

PL16720421T

Other languages

English (en)

Inventor

Chungen Liang

Kun MIAO

Jianping Wang

Hongying Yun

Xiufang ZHENG

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-08

Filing date

2016-05-04

Publication date

2020-03-31

2016-05-04 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

2020-03-31 Publication of PL3294740T3 publication Critical patent/PL3294740T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL16720421T 2015-05-08 2016-05-04 Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych PL3294740T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
CN2015078507		2015-05-08
CN2016078785		2016-04-08
EP16720421.3A EP3294740B1 (en)	2015-05-08	2016-05-04	Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PCT/EP2016/059961 WO2016180695A1 (en)	2015-05-08	2016-05-04	Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number	Publication Date
PL3294740T3 true PL3294740T3 (pl)	2020-03-31

Family

ID=55910966

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16720421T PL3294740T3 (pl)	2015-05-08	2016-05-04	Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych

Country Status (32)

Country	Link
US (3)	US9708325B2 (pl)
EP (1)	EP3294740B1 (pl)
JP (1)	JP6738352B2 (pl)
KR (1)	KR102690131B1 (pl)
CN (1)	CN107580596B (pl)
AR (1)	AR104528A1 (pl)
AU (3)	AU2016260683B2 (pl)
BR (1)	BR112017023959B1 (pl)
CA (1)	CA2982704C (pl)
CL (1)	CL2017002745A1 (pl)
CO (1)	CO2017009994A2 (pl)
CR (1)	CR20170496A (pl)
DK (1)	DK3294740T3 (pl)
ES (1)	ES2753777T3 (pl)
HR (1)	HRP20191942T1 (pl)
HU (1)	HUE045906T2 (pl)
IL (2)	IL254947B (pl)
LT (1)	LT3294740T (pl)
MX (2)	MX393198B (pl)
MY (1)	MY182353A (pl)
NZ (2)	NZ735648A (pl)
PE (1)	PE20171620A1 (pl)
PH (1)	PH12017502009A1 (pl)
PL (1)	PL3294740T3 (pl)
PT (1)	PT3294740T (pl)
RS (1)	RS59435B1 (pl)
RU (1)	RU2745269C2 (pl)
SG (1)	SG10202108841YA (pl)
SI (1)	SI3294740T1 (pl)
TW (2)	TWI706954B (pl)
UA (1)	UA120450C2 (pl)
WO (1)	WO2016180695A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX393198B (es) *	2015-05-08	2025-03-19	Hoffmann La Roche	Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas
IL284255B (en) *	2016-08-29	2022-07-01	Hoffmann La Roche	7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
ES2894605T3 (es) *	2016-09-13	2022-02-15	Hoffmann La Roche	Tratamiento combinado con un agonista de TLR7 y un inhibidor del ensamblaje de la cápside del VHB
EP3752505B1 (en)	2018-02-12	2023-01-11	F. Hoffmann-La Roche AG	Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
WO2019166432A1 (en) *	2018-02-28	2019-09-06	F. Hoffmann-La Roche Ag	7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CN111072667A (zh) *	2018-10-22	2020-04-28	罗欣药业(上海)有限公司	五元或六元杂环并嘧啶类化合物及其用途
US20220226488A1 (en) *	2019-02-12	2022-07-21	Ambrx, Inc.	Compositions containing, methods and uses of antibody-tlr agonist conjugates
ES2979156T3 (es)	2019-09-20	2024-09-24	Syngenta Crop Protection Ag	Derivados heterocíclicos plaguicidamente activos con sustituyentes que contienen azufre y sulfoximina
US20230131192A1 (en) *	2020-01-27	2023-04-27	Bristol-Myers Squibb Company	1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132590A (ko) *	2020-01-27	2022-09-30	브리스톨-마이어스 스큅 컴퍼니	톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
JP2025522978A (ja)	2022-07-14	2025-07-17	エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト	がんの処置のためのホスホリルプリノン化合物
CN118724963A (zh) *	2023-03-30	2024-10-01	浙江养生堂天然药物研究所有限公司	含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4189048B2 (ja)	1997-12-26	2008-12-03	大日本住友製薬株式会社	複素環化合物
KR20080006004A (ko) *	2005-05-04	2008-01-15	화이자 리미티드	암 및 ｃ형 간염과 같은 바이러스 감염의 치료를 위한톨-유사 수용체 조절제인 2-아미도-6-아미노-8-옥소퓨린유도체
CN101239980B (zh)	2008-02-18	2011-06-22	靳广毅	免疫受体调节剂偶联体前体和偶联体及其应用
NZ593110A (en)	2008-12-09	2013-06-28	Gilead Sciences Inc	pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
WO2011079016A1 (en)	2009-12-22	2011-06-30	Gilead Sciences, Inc.	Methods of treating hbv and hcv infection
TWI555737B (zh)	2011-05-24	2016-11-01	拜耳知識產權公司	含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
IN2014MN00862A (pl)	2011-11-09	2015-04-17	Janssen R & D Ireland
ES2625456T3 (es)	2013-03-29	2017-07-19	Janssen Sciences Ireland Uc	Desazapurinonas macrocíclicas para el tratamiento de infecciones víricas
PL3190113T3 (pl)	2014-08-15	2021-10-25	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Związki pirolopirymidynowe stosowane jako agonista TLR7
MX393198B (es) *	2015-05-08	2025-03-19	Hoffmann La Roche	Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas
IL284255B (en) *	2016-08-29	2022-07-01	Hoffmann La Roche	7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

2016
- 2016-05-04 MX MX2020010949A patent/MX393198B/es unknown
- 2016-05-04 PT PT167204213T patent/PT3294740T/pt unknown
- 2016-05-04 NZ NZ735648A patent/NZ735648A/en not_active IP Right Cessation
- 2016-05-04 SI SI201630473T patent/SI3294740T1/sl unknown
- 2016-05-04 RS RSP20191351 patent/RS59435B1/sr unknown
- 2016-05-04 JP JP2017558397A patent/JP6738352B2/ja active Active
- 2016-05-04 WO PCT/EP2016/059961 patent/WO2016180695A1/en not_active Ceased
- 2016-05-04 HR HRP20191942TT patent/HRP20191942T1/hr unknown
- 2016-05-04 EP EP16720421.3A patent/EP3294740B1/en active Active
- 2016-05-04 LT LT16720421T patent/LT3294740T/lt unknown
- 2016-05-04 BR BR112017023959-0A patent/BR112017023959B1/pt active IP Right Grant
- 2016-05-04 DK DK16720421T patent/DK3294740T3/da active
- 2016-05-04 MY MYPI2017704175A patent/MY182353A/en unknown
- 2016-05-04 CR CR20170496A patent/CR20170496A/es unknown
- 2016-05-04 UA UAA201712023A patent/UA120450C2/uk unknown
- 2016-05-04 CN CN201680026493.3A patent/CN107580596B/zh active Active
- 2016-05-04 HU HUE16720421A patent/HUE045906T2/hu unknown
- 2016-05-04 PE PE2017002102A patent/PE20171620A1/es unknown
- 2016-05-04 SG SG10202108841YA patent/SG10202108841YA/en unknown
- 2016-05-04 KR KR1020177035298A patent/KR102690131B1/ko active Active
- 2016-05-04 PL PL16720421T patent/PL3294740T3/pl unknown
- 2016-05-04 ES ES16720421T patent/ES2753777T3/es active Active
- 2016-05-04 NZ NZ775222A patent/NZ775222A/en unknown
- 2016-05-04 AU AU2016260683A patent/AU2016260683B2/en not_active Ceased
- 2016-05-04 RU RU2017142577A patent/RU2745269C2/ru active
- 2016-05-04 MX MX2017014033A patent/MX376761B/es active IP Right Grant
- 2016-05-04 CA CA2982704A patent/CA2982704C/en active Active
- 2016-05-05 AR ARP160101278A patent/AR104528A1/es unknown
- 2016-05-06 TW TW105114192A patent/TWI706954B/zh active
- 2016-05-06 TW TW109131169A patent/TWI768467B/zh active
- 2016-05-06 US US15/148,309 patent/US9708325B2/en active Active
2017
- 2017-06-13 US US15/621,080 patent/US10399983B2/en active Active
- 2017-09-29 CO CONC2017/0009994A patent/CO2017009994A2/es unknown
- 2017-10-09 IL IL254947A patent/IL254947B/en active IP Right Grant
- 2017-10-30 CL CL2017002745A patent/CL2017002745A1/es unknown
- 2017-11-03 PH PH12017502009A patent/PH12017502009A1/en unknown
2019
- 2019-08-02 US US16/530,229 patent/US11242345B2/en active Active
2020
- 2020-10-14 AU AU2020256348A patent/AU2020256348B2/en not_active Ceased
2021
- 2021-02-09 IL IL280769A patent/IL280769B2/en unknown
2022
- 2022-06-29 AU AU2022204666A patent/AU2022204666A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP6738352B2 (ja)	2020-08-12
AU2020256348A1 (en)	2020-11-12
CR20170496A (es)	2017-12-05
IL280769B2 (en)	2023-07-01
KR20180003612A (ko)	2018-01-09
IL280769B1 (en)	2023-03-01
CN107580596B (zh)	2020-07-14
MX393198B (es)	2025-03-19
US20200109144A1 (en)	2020-04-09
CN107580596A (zh)	2018-01-12
US10399983B2 (en)	2019-09-03
RS59435B1 (sr)	2019-11-29
AR104528A1 (es)	2017-07-26
BR112017023959B1 (pt)	2023-05-02
AU2016260683A1 (en)	2017-10-12
NZ735648A (en)	2023-06-30
CA2982704C (en)	2023-10-24
CO2017009994A2 (es)	2018-02-20
DK3294740T3 (da)	2019-11-04
MY182353A (en)	2021-01-20
AU2020256348B2 (en)	2022-06-16
CA2982704A1 (en)	2016-11-17
PT3294740T (pt)	2019-10-29
MX2020010949A (es)	2022-06-16
HRP20191942T1 (hr)	2020-01-10
TWI706954B (zh)	2020-10-11
IL254947A0 (en)	2017-12-31
KR102690131B1 (ko)	2024-07-31
HUE045906T2 (hu)	2020-01-28
ES2753777T3 (es)	2020-04-14
MX2017014033A (es)	2018-03-01
SI3294740T1 (sl)	2019-12-31
UA120450C2 (uk)	2019-12-10
SG10202108841YA (en)	2021-09-29
AU2022204666A1 (en)	2022-07-21
PE20171620A1 (es)	2017-11-02
JP2018515509A (ja)	2018-06-14
EP3294740A1 (en)	2018-03-21
RU2745269C2 (ru)	2021-03-22
TW202108584A (zh)	2021-03-01
IL280769A (en)	2021-04-29
PH12017502009A1 (en)	2018-03-26
IL254947B (en)	2021-02-28
NZ775222A (en)	2024-09-27
US20160326177A1 (en)	2016-11-10
TWI768467B (zh)	2022-06-21
EP3294740B1 (en)	2019-09-04
MX376761B (es)	2025-03-07
TW201716410A (zh)	2017-05-16
HK1247925A1 (zh)	2018-10-05
US9708325B2 (en)	2017-07-18
AU2016260683B2 (en)	2020-10-29
WO2016180695A1 (en)	2016-11-17
US20170275286A1 (en)	2017-09-28
CL2017002745A1 (es)	2018-05-18
US11242345B2 (en)	2022-02-08
RU2017142577A (ru)	2019-06-10
RU2017142577A3 (pl)	2019-10-31
LT3294740T (lt)	2019-11-25
BR112017023959A2 (pt)	2018-07-17

Publication	Publication Date	Title
IL280769B1 (en)	2023-03-01	Novel sulfonimidylpurinone compounds and their history for the treatment and prevention of virus infection
IL284255A (en)	2021-07-29	7-substituted sulfonimidylpurinone compounds for the treatment and prevention of viral infection
IL245436A0 (en)	2016-06-30	New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL246449A0 (en)	2016-08-31	6-compressed new heteroaryldihydropyrimidines for the treatment and prevention of hepatitis b virus infection
IL263972A (en)	2019-01-31	Dihydropyranopyrimidines for the treatment of viral infections
SG11201509463YA (en)	2015-12-30	6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ZA201705634B (en)	2018-12-19	Quinoline derivatives for use in the treatment or prevention of viral infection
EP3280422A4 (en)	2018-12-05	Compositions and methods for the treatment of hbv infection
SG11201702766YA (en)	2017-05-30	Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
SI3137078T1 (sl)	2019-08-30	Zdravljenje okužbe s hepatitis delta virusom
ZA201900770B (en)	2019-12-18	7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
LT3504210T (lt)	2021-05-10	Nauji 7 padėtyje pakeisti sulfonimidoilpurinono junginiai, skirti viruso sukeliamos infekcijos gydymui ir profilaktikai
ZA201604784B (en)	2019-12-18	Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection